Tag: clinical trial
-
New Tanzanian Malaria Vaccine SUM-101 Shows Strong Immune Response in Early Trials
Promising early results for SUM-101 in Tanzanian adults A new experimental malaria vaccine, SUM-101, has generated encouraging immune responses in its first human trial conducted with Tanzanian adults who have prior exposure to malaria. The study, conducted in Dar es Salaam and led by researchers including Aina-ekisha Kahatano and Maxmillian Mpina, aims to assess safety,…
-
SUM-101 Malaria Vaccine Shows Strong Immune Response
Overview of the SUM-101 Trial A new experimental malaria vaccine known as SUM-101 has generated hopeful results in its initial testing phase. Conducted among Tanzanian adults who have lived with malaria exposure, the early trial aimed to assess the vaccine’s safety and its ability to stimulate the immune system — a key step before larger…
-
CRISPR Gene-Editing Shows Promise in Lowering Cholesterol in Early Study
New CRISPR-based therapy reduces cholesterol in a small early study A recent small-stage study has sparked cautious optimism in the fight against high cholesterol. Researchers tested an experimental gene-editing therapy delivered by a single infusion to participants with elevated cholesterol levels. The approach uses CRISPR gene editing to target and alter the body’s pathways that…
-
CRISPR Breakthrough: Gene-Editing Drug Lowers High Cholesterol in Early Trial
New Hope for High Cholesterol: A First Look at a CRISPR-Based Therapy In a small, early-stage study, researchers tested an experimental gene-editing drug designed to lower levels of LDL cholesterol, the type often linked to heart disease. The trial involved 15 volunteers who received a single infusion. While the study is preliminary, the findings suggest…
-
CRISPR Gene Editing Shows Promise in Lowering Cholesterol in Initial Study
CRISPR Gene Editing: A Bold Step in Cholesterol Management Scientists are exploring a groundbreaking approach to fighting high cholesterol using CRISPR gene-editing technology. In a small, early clinical trial, researchers administered a single infusion of an experimental gene-editing drug to a group of volunteers with elevated cholesterol. The results offered a glimmer of hope that…
-
Groundbreaking 4.4 Million Grant Funds First Study of Prefrontal Cortical Stimulation in Severe Bipolar Disorder
Overview of the Breakthrough Funding A University of Minnesota Medical School research team led by Dr. Ziad Nahas has secured a $4.4 million grant to launch the first-in-the-world study assessing prefrontal cortical stimulation as a treatment for severe bipolar disorder. The project, supported by Breakthrough Discoveries, marks a pivotal step in exploring innovative neuromodulation techniques…
-
Pioneering Breakthrough: $4.4M Grant Funds First Study of Prefrontal Cortex Stimulation in Severe Bipolar Disorder
Groundbreaking Funding Sparks a New era in bipolar disorder research A University of Minnesota Medical School team led by Dr. Ziad Nahas has secured a $4.4 million grant to launch what experts say could be a landmark study in the treatment of severe bipolar disorder. The project will investigate prefrontal cortical stimulation, a cutting-edge neuromodulation…
-
Stereotactic Body Radiation Therapy in Inoperable Pancreatic Cancer: Insights from the TORPEDO Phase II Randomised Trial
Overview: The TORPEDO Trial and the Challenge of PDAC Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with many patients presenting with tumors that are inoperable or unsuitable for conventional curative surgery. In this context, the TORPEDO trial investigates the potential of stereotactic body radiation therapy (SBRT) as a treatment option to…
-
AI-Powered App Matches Human-Led Diabetes Prevention Programs in Prediabetes Trial
AI-Powered Diabetes Prevention: A Milestone in Prediabetes Care A landmark randomized trial from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health shows that an AI-powered lifestyle intervention app can reduce the risk of developing type 2 diabetes in adults with prediabetes at rates comparable to traditional, human-led programs. Published in JAMA…
-
AI-Powered Diabetes Prevention: AI DPP Matches Human-Led Programs
Unlocking Equal Ground: AI-Driven DPP Learning from Real-World Trials In a landmark study, researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced diabetes risk at rates comparable to traditional, human-led programs. The work, funded by the National Institutes of Health…